Acceder

Chicharros USA - bolsa internacional

90.7K respuestas
Chicharros USA - bolsa internacional
178 suscriptores
Chicharros USA - bolsa internacional
Página
6,222 / 11,393
#49769

Re: Chicharros USA - bolsa internacional

AGRX

Yo me voy a quedar en esta a largo, si la compra J & J por lo menos duplicará el precio, ahora está a 2.44. El resto de acciones que tengo para ir especulando
#49770

Re: Chicharros USA - bolsa internacional

CLSN


LAWRENCEVILLE, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the first quarter ended March 31, 2020 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Friday, May 15, 2020.


To participate in the call, interested parties may dial 1-800-367-2403 (Toll-Free/North America) or 1-334-777-6978 (International/Toll) and ask for the Celsion Corporation First Quarter 2020 Earnings Call (Conference Code: 6901311) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at www.celsion.com. The call will be archived for replay on Monday, May 18, 2020 and will remain available until June 1, 2020. The replay can be accessed at 1-719-457-0820 or 1-888-203-1112 using Conference ID: 6901311. An audio replay of the call will also be available on the Company's website, www.celsion.com, for 90 days after 2:00 p.m. EDT Friday, May 15, 2020.


About Celsion Corporation


Celsion is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit: http://www.celsion.com. (CLSN-FIN).

Edito: esta empresa hace una cosa rara para combatir el cáncer....coge doxorubicina, un agente de quimio, lo encapsula en liposomas, manda los liposomas a la zona del cáncer, y una vez allí, aplica radiación para generar calor, fundir la grasita y liberar el agente de quimio......puede estar bien, pero siempre me ha parecido un poco de película del futuro...jajajajaja

#49771

Re: Chicharros USA - bolsa internacional

ZOM
Vendidas a 0,32 las compradas a 0,24   no me fio un pelo

Más vale pájaro en mano que "buitre" volando ...

#49772

Re: Chicharros USA - bolsa internacional

agrx

Se disparan
#49773

Re: Chicharros USA - bolsa internacional

MARA vendidas a 0,76
#49774

Re: Chicharros USA - bolsa internacional

AGRX

No es un chicharro y es una buena empresa para medio y largo plazo
#49775

Re: Chicharros USA - bolsa internacional

Ojo vizu 16/100 y con mucho volumesn como recomendó framus bien
#49776

Re: Chicharros USA - bolsa internacional

Ojo, KTOV me está sorprendiendo hoy. Habemus volumen...
Te puede interesar...

- No hay entradas a destacar -

- No hay entradas a destacar -